COVID-19 treatment

June 21, 2020

Major U.S. trial closes showing no benefit for hydroxychloroquine in COVID-19

The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm. 

By VUMC News and Communications
June 12, 2020

TERAVOLT registry tracks outcomes of treatments among people with thoracic cancers sickened by COVID-19

New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.

By Tom Wilemon
June 9, 2020

Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.

By Bill Snyder
June 4, 2020

Remdesivir helps reduce COVID-19 recovery time: study

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

By Bill Snyder
May 28, 2020

Multinational consortium reports COVID-19 impact on cancer patients

People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet and simultaneously presented at ASCO20 Virtual, also revealed cancer-specific factors associated with increased mortality.

By Tom Wilemon
May 22, 2020

Scenes from the pandemic, collection three: glimpses into life during COVID-19 at Vanderbilt

As Vanderbilt continues to care for COVID-19 patients, other care, including clinic visits and elective surgeries, begin again.

By Wayne Wood
May 21, 2020

VUMC research ramps up in COVID-19 transition

As Nashville cautiously begins to emerge from its two-month-long COVID-19 Safer at Home response, so too are the labs and facilities at Vanderbilt University Medical Center.
By Bill Snyder
May 21, 2020

Team uses imaging to study ways the heart is affected by coronavirus

Researchers are using imaging and diagnostic pathology to examine postmortem hearts donated by victims of COVID-19 to gain a better understanding of how the coronavirus that causes COVID-19 affects the heart.
By Leigh MacMillan
May 20, 2020

Children’s Hospital lands grant from Hyundai Hope On Wheels

Monroe Carell Jr. Children’s Hospital at Vanderbilt has been awarded a grant from longtime philanthropic partner Hyundai Hope On Wheels to support a COVID-19 drive-thru testing site at Nissan Stadium, home of the Tennessee Titans.
By Christina Echegaray
May 19, 2020

VUMC Research Enterprise begins ramping up

As Nashville cautiously begins to emerge from its two-month-long COVID-19 Safer at Home response, so too are the labs and facilities at Vanderbilt University Medical Center.
By Bill Snyder
May 15, 2020

Core principles guiding the COVID-19 response and beyond

During a first-ever virtual leadership assembly necessitated through social distancing, Vanderbilt University Medical Center leaders answered questions about the Medical Center’s response to COVID-19 so far and what the future could hold.
By Holly Fletcher
May 1, 2020

Dr. Jeff Balser on a careful approach to restarting elective services

As public officials begin to lift restrictions due to COVID-19, I want to spend a few minutes today talking about our next steps at VUMC.
By VUMC News and Communications
April 30, 2020

Antibody finding raises hopes for Marburg, COVID-19 treatments

Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody “cocktails” to counter viral infection.
By Bill Snyder